Epizyme downgraded by Cowen with a new price target
$EPZM
Biotechnology: Pharmaceutical Preparations
Health Care
Cowen downgraded Epizyme from Outperform to Market Perform and set a new price target of $1.50
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/28/2022 | $1.50 | Outperform → Market Perform | Cowen |
| 6/27/2022 | Outperform → Neutral | Wedbush | |
| 3/2/2022 | $15.00 → $10.00 | Buy | HC Wainwright & Co. |
| 8/10/2021 | $10.00 → $5.00 | Equal-Weight → Underweight | Morgan Stanley |
| 8/10/2021 | $36.00 → $15.00 | Buy | HC Wainwright & Co. |
15-12G - Epizyme, Inc. (0001571498) (Filer)
EFFECT - Epizyme, Inc. (0001571498) (Filer)
EFFECT - Epizyme, Inc. (0001571498) (Filer)
Cowen downgraded Epizyme from Outperform to Market Perform and set a new price target of $1.50
Wedbush downgraded Epizyme from Outperform to Neutral
HC Wainwright & Co. reiterated coverage of Epizyme with a rating of Buy and set a new price target of $10.00 from $15.00 previously
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
4 - Epizyme, Inc. (0001571498) (Issuer)
TAZVERIK® (tazemetostat) Net Product Revenue of $11.0 Million for 2Q 2022; Total End User Demand Grew 17% vs. 1Q 2022 First Patient Dosed in the SET-101 Phase 1/1b Study of EZM0414, the Company's Novel, First-in-Class, Oral SETD2 Inhibitor Merger with Ipsen Expected to Close in 3Q 2022 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today reported second quarter 2022 financial results and provided a business update. "I am pleased with the progress we made as an organization in the second quarter. In addition to the growth of TAZVERIK net product
Extension allows for satisfaction of the HSR Condition as outlined in the Merger Agreement Epizyme stockholders are encouraged to tender their shares to the offer today Regulatory News: Ipsen S.A. ((Euronext: IPN, OTC:IPSEY) today announced that Hibernia Merger Sub, Inc. (Purchaser), its wholly owned indirect subsidiary, has extended the expiration time for the previously announced tender offer to purchase all of the issued and outstanding shares of common stock (the Shares) of Epizyme, Inc. (NASDAQ:EPZM) (Epizyme) at a price of $1.45 per share, to the holder in cash, without interest and less applicable withholding taxes, plus one non-transferable contingent value right (CVR) per Sha
Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini
Appointment of Jerald Korn as Chief Operating Officer First Patient Dosed in the Randomized Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study of Tazemetostat in Combination with R2 Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced a clinical update as well as the appointment of Jerald Korn as Chief Operating Officer, reporting to President and Chief Executive Officer, Grant Bogle. "We are excited to welcome Jerald to Epizyme at a pivotal time for the organization," said Mr. Bogle. "Jerald's breadth of experienc
MILAN--(BUSINESS WIRE)--Enthera Pharmaceuticals (“Enthera”), a biotech company developing disease-modifying biologics to transform the therapeutic paradigm of specific autoimmune conditions by re-establishing stem cell capabilities in a non-traditional way, announces that it has appointed Kazumi Shiosaki to its Board of Directors, and Lisa Olson to its Scientific Advisory Board. Kazumi brings experience as both an entrepreneur and an investor within the field of biotechnology. She is currently the CEO of Twentyeight-Seven, a biotech company focused on novel RNA biology that she co-founded alongside prominent Harvard investigators. Kazumi was also a co-founder and CEO of Mitobridg
Transaction focused on lead asset Tazverik® (tazemetostat), a first-in-class EZH2a inhibitor approved in the U.S. Acquisition to bolster Ipsen's growing oncology presence and leverage its infrastructure Ipsen to commence all-cash tender offer to acquire all outstanding shares of Epizyme for $1.45 per share plus a contingent value right (CVR) of $1.00 per share Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220626005092/en/ Disclaimer: Intended for international media and investor audiences only Ipsen ((Euronext: IPN, OTC:IPSEY) and Epizyme (NASDAQ:EPZM) today announced that they have entered into a defini
TAZVERIK® (tazemetostat) Net Product Revenue of $8.7 Million for 1Q 2022, Supported by Streamlined Operating Expenses which Decreased by 17% in 1Q 2022 vs. 1Q 2021 First Patient Dosed in the Randomized Phase 3 Portion of SYMPHONY-1 (EZH-302), Epizyme's Phase 1b/3 Confirmatory Study Assessing Tazemetostat in Combination with R2 in Follicular Lymphoma (FL) Updated Data from the Phase 1b Portion of SYMPHONY-1 to be Presented at ASCO; Additional Updates Anticipated in 2H 2022 from Tazemetostat and EZM0414 (SETD2 inhibitor) Studies Epizyme (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients again
Epizyme, (NASDAQ:EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies for cancer patients against novel epigenetic targets, today announced that management will host a conference call to discuss its first quarter 2022 financial results and provide a business update on Tuesday, May 10, 2022 at 8:30 a.m. ET. To participate in the conference call, please dial (877) 844-6886 (domestic) or (970) 315-0315 (international) and refer to conference ID 5369344. A live webcast will be available in the investor section of the company's website at www.epizyme.com, and will be archived for 60 days following the call. About Epizyme, Inc.
Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-5) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 08/13/2024. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
Submission status for EPIZYME INC's drug TAZVERIK (SUPPL-4) with active ingredient TAZEMETOSTAT HYDROBROMIDE has changed to 'Approval' on 11/16/2023. Application Category: NDA, Application Number: 211723, Application Classification: Labeling
SC 13G/A - Epizyme, Inc. (0001571498) (Subject)
SC 13D - Epizyme, Inc. (0001571498) (Subject)
SC 13D/A - Epizyme, Inc. (0001571498) (Subject)
According to Benzinga Pro data, during Q2, Epizyme (NASDAQ:EPZM) posted sales of $27.53 million. Earnings were up 35.6%, but Epizyme still reported an overall loss of $35.74 million. In Q1, Epizyme brought in $8.70 million in sales but lost $55.51 million in earnings. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q2, Epizyme posted an ROCE of 1.76%
Epizyme (NASDAQ:EPZM) reported its Q2 earnings results on Tuesday, August 9, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Epizyme beat estimated earnings by 41.67%, reporting an EPS of $-0.21 versus an estimate of $-0.36. Revenue was up $14.52 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.03 which was followed by a 21.16% drop in the share price the next day. Here's a look at Epizyme's past performance: Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021 EPS Estimate -0.35 -0.45 -0.48 -0.62 EPS Actual -0.38 -0.49 -0.64
Epizyme (NASDAQ:EPZM) reported quarterly losses of $(0.21) per share. This is a 66.67 percent increase over losses of $(0.63) per share from the same period last year.